Evidence map›Paper›PMID 23112716›Full record

ReviewSensors (Basel, Switzerland)2012

Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays.

Sephra N Rampersad

Open access · goldAbstract readReview
In one paragraph

Review in Sensors (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 433 papers.

0numbers the graph read from it
0cells of the map it votes in
433citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

433 citing papers in PubMed, 1,026 citations in OpenAlex.

  1. Article
  2. Article
  3. NabioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. High and Selective TrypanocidalMicroorganisms · 2026
    Article
  7. Article
  8. Mechanochemical Synthesis of a TiOJournal of functional biomaterials · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. AdvancingBiology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Epigenomes · 2026
    Article
  19. Article
  20. Article

373 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Sephra N RampersadDepartment of Life Sciences, The University of the West Indies, West Indies, St Augustine, Trinidad and Tobago. Sephra.Rampersad@sta.uwi.edu
University of the West Indies · TT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate prediction of the adverse effects of test compounds on living systems, detection of toxic thresholds, and expansion of experimental data sets to include multiple toxicity end-point analysis are required for any robust screening regime. Alamar Blue is an important redox indicator that is used to evaluate metabolic function and cellular health. The Alamar Blue bioassay has been utilized over the past 50 years to assess cell viability and cytotoxicity in a range of biological and environmental systems and in a number of cell types including bacteria, yeast, fungi, protozoa and cultured mammalian and piscine cells. It offers several advantages over other metabolic indicators and other cytotoxicity assays. However, as with any bioassay, suitability must be determined for each application and cell model. This review seeks to highlight many of the important considerations involved in assay use and design in addition to the potential pitfalls.

Indexed as

AnimalsBiological AssayCell SurvivalColoring AgentsHumansIndicators and ReagentsOxazinesXanthenesColoring AgentsIndicators and ReagentsOxazinesresazurinXanthenesAlamar Bluecell viabilitycytotoxicityresazurin

Identifiers

PMID23112716
PMCPMC3478843
OpenAlexW2004602806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.